As Dr T has pointed out, when comparing bisantrene with other FTO inhibitors, the clinical history or lack thereof is more important than the precise amount by which bisantrene is more potent than its "peers".
I think it's sufficient to say in the "bisantrene among peers" section that bisantrene ticks both boxes, and that brequinar has unpredictable dosing and dangerous auto immune side effects.
RAC Primer, page-164
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |